Category Archives: Pharmacovigilance

Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose

Posted on December 20, 2011 by

Image via Wikipedia Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose AUDIENCE: Neurology, Patients ISSUE: The FDA has received a report of a patie            nt with multiple … Continue reading →

Posted in Adverse event, FDA, Fingolimod, Food and Drug Administration, Gilenya, MedWatch, multiple sclerosis, Pharmacovigilance | Leave a comment